본문으로 바로가기

기술동향

MRC Strategic Review of Human Immunology

  • 등록일2009-01-16
  • 조회수7095
  • 분류기술동향
  • 자료발간일
    2008-12-15
  • 출처
    MRC
  • 원문링크
  • 키워드
    #Immunology#MRC#Human Immunology#인체 면역학
  • 첨부파일

출처 : MRC

 

MRC Strategic Review of Human Immunology

  

TABLE OF CONTENTS


MRC Strategic Review of Human Immunology......................................................1
1 Executive summary.........................................................................................4
  Status of the field.................................................................................................4
  Knowledge Gaps in human immunology research..............................................4
  New technologies and tools .................................................................................5
  A roadmap ............................................................................................................6
  How can the MRC deliver in the short, medium and long-term?.......................7
2 Introduction .....................................................................................................9
3 MRC Strategic Review of Human Immunology ..............................................9
4 MRC investment in human immunology ...................................................... 10
  4.1 Analysis of the MRC’s immunology portfolio .......................................... 10
  4.2 Forms of support...................................................................................... 10
  4.3 Specific areas of research........................................................................ 10
  4.4 Scientific classification ............................................................................. 11
  4.5 MRC initiatives in human immunology research .................................... 11
   4.5.1 Translational vaccine research call ............................................... 11
   4.5.2 Emerging infections and influenza................................................ 12
   4.5.3 Healthcare-associated infections & antimicrobial resistance. 12
   4.5.4 Infections affecting poorer people in developing countries ... 12
5 Some current issues in human immunology................................................ 13
  5.1 Cross-cutting themes in the field of human immunology...................... 13
  5.2 Transplantation ........................................................................................ 13
  5.3 Cancer....................................................................................................... 14
  5.4 Infectious diseases................................................................................... 14
  5.5 Autoimmunity........................................................................................... 15
  5.6 Allergic diseases....................................................................................... 16
6 Knowledge gaps ............................................................................................ 16
  6.1 Innate immunity ...................................................................................... 17
  6.2 Inflammation............................................................................................ 17
  6.3 Immune cell subtypes.............................................................................. 18
   6.3.1 B cell biology ...................................................................................... 18
   6.3.2 T cell biology ...................................................................................... 18
  6.4 Vaccines.................................................................................................... 19
  6.5 Understanding the local immune response ............................................ 19
  6.6 A greater understanding of life-course of the immune system in health and 

       disease........... 20
  6.7 Understanding the life-course of immune diseases ............................... 20
  6.8 A greater understanding of the determinants of disease process and outcomes .... 20
  6.9 Addressing disease complexity ............................................................... 21
  6.10 Biomarkers ............................................................................................... 21
7 New technologies and tools .......................................................................... 21
  7.1 Animal models.......................................................................................... 21
  7.2 In vitro models......................................................................................... 22
  7.3 Novel technologies................................................................................... 22
   7.3.1 Imaging ............................................................................................... 22
   7.3.2 Structural biology.............................................................................. 23
  7.4 Translating our knowledge of human immunology in health and disease..... 23
   7.4.1 Experimental medicine .................................................................... 23
   7.4.2 Cohorts ................................................................................................ 23
   7.4.3 Novel uses for established tools .................................................... 24
   7.4.4 Genome sequencing.......................................................................... 24
   7.4.5 Developing a ‘systems medicine approach’ ................................ 24
   7.4.6 Bioinformatics.................................................................................... 25
8 A roadmap ..................................................................................................... 25
  8.1 Creating an interdisciplinary environment.............................................. 25
  8.2 Building capacity ...................................................................................... 26
   8.2.1 Training ............................................................................................... 26
   8.2.2 Sustainability ..................................................................................... 26
  8.3 Increasing connectivity............................................................................ 27
   8.3.1 Partnering with the industrial sector ........................................... 27
   8.3.2 Partnering with the Health Departments .................................... 28
  8.4 Evaluation of outputs, outcomes and impact ......................................... 28
9 How can the MRC deliver in the short, medium and long-term?................ 29
  9.1 Short-term................................................................................................ 29
   9.1.1 Funding and organisation of new research................................. 29
   9.1.2 Promoting new partnerships .......................................................... 29
   9.1.3 Helping with regulation ................................................................... 30
  9.2 Medium-term............................................................................................ 30
  9.3 Long-term................................................................................................. 31

Appendix 1: Terms of reference and membership.............................................. 32
Appendix 2: Summary slides from the human immunology review panel ........ 33
Appendix 3: Human immunology networks ? possible approaches based
on existing models ........................................................................................ 34

 
1 Executive summary

The purpose of this Strategic Review is to identify significant opportunities and gaps in the field of human immunology research; to examine the MRC’s impact in human immunology
research; and the contributions of the MRC’s extra- and intramural investment now and in the
future. The Strategic Review Panel was chaired by Professor Herb Sewell, University of
Nottingham and a member of the MRC’s Council. The panel included broad human iimmunology expertise, the MRC’s Infections and Immunity Board (IIB) members, experts from academia and industry and corporate MRC Head Office representation. The first meeting was held on 17/18 October followed by a final meeting on 29 November. Although the findings and
recommendations are from the panel itself, we gratefully acknowledge the inputs of a number
of national and international experts, universities, Health Departments and other stakeholders.
 
 

...................(계속)

 

☞ 자세한 내용은 내용바로가기 또는 첨부파일을 이용하시기 바랍니다.

 
 
 
목록 스크랩
관련정보

동향

자료 추천하기

받는 사람 이메일
@
메일 내용